13:52 , Jun 29, 2017 |  BC Innovations  |  Translation in Brief

Tilt a flavin

A team from GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) and the University of Edinburgh has solved a problem that has stymied the development of kynurenine 3-monoxygenase (KMO) inhibitors -- the production of cytotoxic hydrogen peroxide -- and...
07:00 , Jun 22, 2015 |  BC Week In Review  |  Clinical News

Arzerra ofatumumab: Additional Phase III data

Additional data from the open-label, international Phase III COMPLEMENT 2 trial in 365 patients with relapsed CLL showed that IV Arzerra plus fludarabine and cyclophosphamide led to a median PFS, the primary endpoint, of...
07:00 , May 4, 2015 |  BC Week In Review  |  Clinical News

Arzerra ofatumumab: Phase III data

Top-line data from the open-label, international Phase III COMPLEMENT 2 trial in 365 patients with relapsed CLL showed that IV Arzerra plus fludarabine and cyclophosphamide met the primary endpoint of improving PFS vs. fludarabine...
08:00 , Dec 15, 2014 |  BioCentury  |  Strategy

Momenta moving on

Data announced in October represent the first fruits of Momenta Pharmaceuticals Inc.'s novel drug pipeline, which will play a larger role in the company's strategy going forward as it steps back from complex generics. Momenta...
08:00 , Nov 25, 2013 |  BC Week In Review  |  Clinical News

Lampalizumab: Additional Phase II data

Roche's Genentech Inc. unit disclosed the details of an exploratory biomarker from the single-blind Phase II MAHALO trial evaluating lampalizumab to treat GA associated with AMD. In August, data from 129 patients in MAHALO showed...
01:57 , Nov 19, 2013 |  BC Extra  |  Clinical News

Genentech details biomarkers for lampalizumab

The Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) disclosed the details of an exploratory biomarker for the company's lampalizumab ( RG7417), which is in development to treat geographic atrophy (GA), an advanced form of dry...
07:00 , Sep 2, 2013 |  BC Week In Review  |  Company News

Arcturus Therapeutics, Marina Biotech deal

Marina sold its Unlocked Nucleobase Analog (UNA) patents for the development of RNAi therapeutics to Arcturus. Marina retains a non-exclusive license to the technology. UNAs are acyclic ribonucleoside analogs in which the bond between the...
08:00 , Dec 10, 2012 |  BC Week In Review  |  Company News

Marina Biotech, Tekmira Pharmaceuticals Inc. deal

Marina Biotech granted Tekmira a non-exclusive, worldwide license to develop and commercialize RNAi therapeutics using Marina Biotech's Unlocked Nucleobase Analog (UNA) technology for undisclosed indications. Marina Biotech will receive an undisclosed upfront payment and is...
07:00 , Oct 11, 2012 |  BC Innovations  |  Cover Story

Ember: warming up to brown fat

A team led by Boston-area researchers has shown that inhibiting a cation channel dubbed TRPV4 induced white fat cells to behave like brown fat, thereby protecting mice from diet-induced obesity and insulin resistance.1Ember Therapeutics Inc....
07:00 , Oct 11, 2010 |  BC Week In Review  |  Company News

caprotec sales and marketing update

caprotec bioanalytics GmbH, Berlin, Germany   Business: Proteomics   caprotec bioanalytics launched three new caproKits to investigate small molecule-protein interactions and discover, identify and characterize proteins: Dasatinib caproKit, C2 cAMP caproKit and Biotin Capping kit. The Dasatinib...